摘要
目的分析脑梗死者以阿替普酶静脉溶栓、阿司匹林配合治疗的效果。方法方便选取2017年8月-2018年10月期间67例脑梗死者为研究对象,按数字表法随机分组,对照组共34例(阿司匹林)、观察组共33例(加阿替普酶静脉溶栓),观察患者凝血指标、D-二聚体(D-D)、血小板(PLT)、神经功能治疗前后变化,比较两组疗效差异,统计不良反应发生。结果治疗后观察组PT为(24.1±3.5)s、APTT为(43.7±9.3)s、PLT为(387.9±46.1)×10~9/L,高于对照组(20.9±3.1)s、(30.1±9.4)s、(284.2±48.3)×10~9/L,观察组D-D为(0.8±0.1)mg/L,低于对照组(0.9±0.1)mg/L,差异有统计学意义(t=3.965、5.952、8.985、4.092,P<0.05);观察组治疗率为90.9%,高于对照组79.4%,差异有统计学意义(χ^2=5.229,P<0.05);观察组发生率为9.1%,与对照组11.8%比较差异无统计学意义(χ^2=0.390,P>0.05)。结论对脑梗死者以阿替普酶静脉溶栓、阿司匹林配合治疗,效果理想、不良反应少,患者血液高凝状态得到改善,血管栓塞得到控制。
Objective To analyze the effect of intravenous thrombolysis with Alteplase plus Aspirin in cerebral infarction patients. Methods A total of 67 cerebral infarction patients treated from August 2017 to October 2018 in our hospital were convenient selected. They were randomly divided into control group(n=34) and observation group(n=33). The control group took Aspirin, and the observation group took Aspirin plus intravenous thrombolysis with Alteplase. The coagulation indicators, D-dimer(D-D) and blood platelet(PLT) contents, neurological function, therapeutic effect and adverse reactions were observed and compared. Results After treatment, the PT(prothrombin time), APTT(activated partial thromboplastin time) and PLT values in the observation group were(24.1±3.5)s,(43.7±9.3)s and(387.9±46.1)×10~9/L, which were higher than those in the control group [(20.9±3.1)s,(30.1±9.4)s,(284.2±48.3)×10~9/L]. The D-D contents in the observation group was(0.8±0.1)mg/L,which was lower than that in the control group(0.9±0.1)mg/L,the difference was statistically significant(t=3.965、5.952、8.985, 4.092, P<0.05). The cure rate in the observation group was 90.9%, which was higher than that of the control group(79.4%),the difference was statistically significant(χ^2=5.229,P <0.05). The rate of adverse event between the observation group(9.1%) and control group(11.8%) was not significantly different(χ^2=0.390, P>0.05). Conclusion The intravenous thrombolysis with Alteplase plus Aspirin can increase the therapeutic effect, reduce the adverse event rate, improve the hypercoagulable state and control the vascular thrombosis.
作者
黄汉烽
HUANG Han-Feng(Department of Internal Medicine III,Jiexi County People爷s Hospital,Jieyang,Guangdong Province,515400 China)
出处
《中外医疗》
2019年第12期98-100,140,共4页
China & Foreign Medical Treatment
关键词
凝血指标
阿司匹林
D-二聚体
脑梗死
阿替普酶
静脉溶栓
Coagulation indicators
Aspirin
D-dimer
Cerebral infarction
Alteplase
Intravenous thrombolysis
